Consilient Health has launched Rewisca (pregabalin) for adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Rewisca is the first branded alternative to Lyrica (pregabalin) capsules from Pfizer for these two indications, and its launch is said to have potential to help the NHS make cost savings in these patients.
Rewisca has been launched by Consilient Health with the Consilient Health Scheme - a bespoke ordering and supply scheme that ensures Rewisca is only supplied for patients prescribed Rewisca by brand.
Ahmed Al-Derzi, CEO Consilient Health said: “Ensuring the very best patient outcomes whilst securing cost savings is currently a key priority for the NHS. We are pleased we have been able to launch Rewisca allowing the NHS to start making immediate savings. The price of Rewisca, for use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of GAD in adults, is 25% below that of the Drug Tariff price for pregabalin capsules.
We fully respect the current patent protection of Lyrica for use in pain, but appreciate that the situation has created uncertainty for our customers around the use of generic pregabalin. In response, we have invested in the development and design of the new Consilient Health Scheme which helps ensure Rewisca can be prescribed with confidence and dispensed with confidence for its two indications. Over the past 10 years we have continued to demonstrate that we are 100% committed to working in partnership with the NHS nationally and CCGs on a local level and we are delighted to have been able to launch the first alternative brand in this market.”